Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS... Procyon Corporation Announces Amerx Healthcare Subsidiary Has Obtained #1 Ranking in Podiatry Management's 25th Annual Survey for Amerigel Wound & Skin Care Products
Tuesday May 6, 1:00 pm ET
CLEARWATER, FL--(MARKET WIRE)--May 6, 2008 -- Procyon Corporation (OTC BB:PCYN.OB - News), a Clearwater, Florida-based company whose subsidiaries include Amerx Health Care Corporation -- w.w.w.Amerigel.com -- today announced that the recently published "Podiatry Management 25th Annual Survey" of podiatrists places Amerigel® at the top of two lists regarding physician recommended treatment products. D.P.M.'s from around the nation were asked to respond to survey questions to determine industry trends.
ADVERTISEMENT
According to the Annual Survey, Amerigel® was ranked as the #1 topical dressing of choice following matrixectomy for the 5th consecutive year. Amerigel® Wound Dressing represented a definitive lead over other topical dressings recommended for post-matrixectomy treatment with 45% of the respondents reporting it as their first choice for treatment, a 17% increase over the previous year's percentage. Amerigel® was named the treatment of choice by more podiatrists than all the other name brands that were included in the survey combined.
Amerigel® Wound Dressing was also ranked as the #1 product recommended for non-graft treatment of wounds and ulcers for the second straight year. Twenty-three percent of the respondents reported that they recommended Amerigel® for non-graft wound/ulcer treatments, an 8% increase over the previous year's response.
Amerigel® products carry the APMA Seal of Approval. Amerigel® products are made with a proprietary product rich with natural tannins, known as Oakin®. Oakin®, exclusive to the Amerigel® product line, delivers these known benefits to patients in need of solving skin and wound problems.
brick by brick....
Great quarter, so much for being able to add any more shares on the cheap! I thought this quarter would be flatish but perhaps the announcement of a buy back was in part a hint at things growing.
I wonder if they'll PR it Monday and give any indication about prospects going forward.
Didn't read the full Q yet will be curious to see where the growth is.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5442757
Edit:
Just read this part so while higher prices going forward will be good the big jump may be due to stocking
Sales also increased in the second quarter because we notified our customers of a coming price increase that took effect January 1, 2008.
A Nice article on the company though it is from March.
http://tampabay.bizjournals.com/tampabay/stories/2007/03/12/smallb1.html?t=printable
I've talk to Ms. Anderson a couple times... She very careful with her words.. I didn't sense she was comfortable discussing anything about the future... very conservative talk..
I too think the same as you..
I don't know them either (never had contact with the company) looking through filings and how each division is doing (by memory) I believe it is the younger son is in charge of the Skincare division and it is doing quite well they talk about the Sirius division having a lot of potential but it seems to be declining (though it is quite small). Wonder if that is more management or product related?
I like the potential of the company. It has nice stable growth (overall) so I don't see much downside risk too. Would follow it a lot closer if I could get some decent shares (I try not to chase stocks though).
Maybe the Anderson's didn't like share pps getting down below 40?
They got options down there in the 20's..
I think the future of this company is very good.. It seems after Mr. Anderson passed, maybe all the legal stuff is now over... young men and good woman operate this company... Although I don't know these folks, second generation kids sometime take companies to great heights.
I was disappointed to see the buyback.... Or at least they could have waited a while till I built up a decent position.
Unless they purchases are via private transaction I can't see them buying anywhere near 1% much less 10%! But still just having it out there probably prevents any more cheap shares anytime soon.
10Q out EPS of $0.003549168
12 month trailing $0.05526267
at a $.50 PPS makes for it trading at TTM PE 9
News.. Procyon Corporation (OTCBB: PCYN) Reports Seventeenth Consecutive Profitable Quarter
Procyon Corporation (OTCBB: PCYN) (the "Company") Today Reported Its Audited Earnings for the Fiscal Year Ended June 30, 2007
Procyon Corporation, a Florida-based company (OTCBB: PCYN) (the "Company"), whose subsidiaries are Amerx Health Care Corporation -- www.Amerigel.com -- and Sirius Medical Supply -- www.siriusmedical.com -- released its 10-KSB for its fiscal year ended June 30, 2007. The report reflects the 17th consecutive quarter and 3rd consecutive year that Procyon Corporation has posted a profit for its operations. Net sales during fiscal 2007 were approximately $2,536,577, an increase of approximately 10% over the same period one year ago. We believe that the sales increase was a result of further penetration within existing target markets. Gross profit for the year was approximately $1,936,402, reflecting an 8% increase over the prior fiscal year. Gross profit was approximately 76% of net sales for this period. Net income for fiscal 2007 increased by 46% to $498,380. This resulted in a $0.06 basic net income per common share for the fiscal year. The full report can be found in the latest 10-KSB filing made with the Securities and Exchange Commission on September 27, 2007, at www.sec.gov.
Operating expenses increased as the company purchased a new accounting system equipped to handle growth, acquired our office building, which we had previously leased, and sought to expand its operations by adding additional staff. Additional costs were also incurred in this reporting period to promote a new product in AmeriGel's professional line of proprietary wound and skin care products, a Post-Surgical Kit. The initial response to the Post-Surgical Kit indicates that it is being well received by the health care industry and management anticipates this will be reflected in the Company's future financial results.
Company assets have more than doubled since the beginning of the fiscal year, reflected by an increase in current assets, deferred tax asset, property and equipment.
AmeriGel proprietary line of wound and skin care products are made with Oakin(TM), proven to enhance the natural healing of wounds, reduce inflammation and prevent infection. The AmeriGel professional line of products includes the flagship AmeriGel Hydrogel Wound Dressing, AmeriGel Saturated Gauze Pads, AmeriGel Post-OP Surgical Kits, AmeriGel Care Lotion, AmeriGel Barrier Lotion and AmeriGel Wound Wash.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: When used in this release, the words "may," "will," "expect," "anticipate," "continue," "estimate," "project," "intend," "believe," and similar expressions, variations or the negative of these words, and any statement regarding possible or assumed future results of operations of our business, the markets for our products, anticipated expenditures, regulatory developments or competition, or other statements regarding matters that are not historical facts, are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Such forward-looking statements are subject to various risks and uncertainties, including, but not limited to, the following: business conditions in the skin and wound care market and the general economy, competitive factors, changes in product mix, production delays, manufacturing capabilities, and other risks or uncertainties detailed in other of the Company's Securities and Exchange Commission filings. Additional information on these and other factors that could affect our financial results is included in our Form 10-KSB for the year ended June 30, 2006. There may be other factor not mentioned above, in the discussion below or included in our Securities and Exchange Commission filings that may cause actual results to differ materially from any forward-looking statements. The reader should not place undue reliance on any forward-looking statements. Neither the Company nor any of its corporate officers or key employees assumes any obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Regina Anderson
President/CEO
Procyon Corporation
1300 S Highland Ave
Clearwater, FL 33756
727.447.2998
rwa@procyondirect.com
News.... RECEIPT OF FEDERAL SUPPLY NUMBER WITH GENERAL SERVICES ADMINISTRATION
-------------------------------------------------------------
"Clearwater, Fl * July 23, 2007 - Procyon Corporation (OTC BB * PCYN) (the *
Company *) today announced that its Amerx HealthCare subsidiary received a
Federal Supply Schedule Number from the United States General Services
Administration on July 15, 2007.
Amerx HealthCare Corporation received a Federal Supply Schedule number from the
Government Services Administration for a 5-year period beginning 7/15/07.
Receipt of this number will afford Amerx the opportunity to provide its
proprietary line of wound and skin care products to Federal agencies including
the Department of Veterans Affairs, Department of Defense, Coast Guard, and
Public Health Services including Indian Health. This Federal supply number will
allow individual Federal agencies to add Amerigel(R) products to their local
formulary.
AmeriGel's proprietary line of wound and skin care products is made with
Oakin(R), proven to enhance the natural healing of wounds, reduce inflammation
and prevent infection. They include AmeriGel(R) Wound Dressing, AmeriGel(R)
Hydrogel Saturated Gauze Dressing, Amerigel(R) Care Lotion, Amerigel(R) Saline
Wound Wash, Amerigel(R) Barrier Lotion and Amerigel(R) Post-Op Surgical Kits.
Amerx began operations in 1993 and manufacturers proprietary wound and skin
products, including the Amerigel(R) Skin and Wound Care product line.
Amerigel(R) products have been reviewed by the FDA. All manufacturing is done in
the US and complies with rigid GMP requirements. Amerx HealthCare continues its
research and development of innovative and high-quality products to medical
professionals and to the consumer. Amerigel's cost-effective products are
available over-the-counter and do not require a prescription.
this has been a complete...
failure for me in getting filled for several months now. The price has just run away from my orders. Even had a good size order in at the ask and then - wham - they upped it away from me. Has happened several times. aaaahhhhhhhhhhgggggggg!!!
NEWS.... Reports Sixteenth Consecutive Profitable Quarter May 23, 2007 - 4:24 PM EDT
Procyon Corporation today reported its unaudited earnings for the fiscal quarter and nine months ended March 31, 2007.
Procyon Corporation, a Florida based company (the "Company"), whose subsidiaries are Amerx Health Care Corporation -- www.Amerigel.com -- and Sirius Medical Supply -- www.siriusmedical.com -- released its 10-QSB for its third fiscal quarter ended March 31, 2007. The report reflects the 16th consecutive quarter that Procyon Corporation has posted a profit for its operations. Net sales for the third quarter of fiscal 2007 were approximately $698,015, an increase of approximately 12% over the same period one year ago. The sales increase was a result of further penetration within existing target markets. Gross profit for the third quarter was approximately $548,142, reflecting a 12% increase over the same period of the prior fiscal year. Gross profit was approximately 79% of net sales for this period. Net income for the third quarter fiscal 2007 period increased by 73% to $219,536. This resulted in a $0.03 basic net income per common share for the quarter reported. The full report can be found in the latest 10-QSB filing made with the Securities and Exchange Commission on May 14,2007, at www.sec.gov.
Operating expenses increased as the company sought to expand its operations by adding additional staff. Additional costs were also incurred in this reporting period to promote a new product in the AmeriGel professional line of proprietary wound and skin care products, a Post Surgical Kit. The initial response to the Post-Surgical Kit indicates that it is being well received by the health care industry and management anticipates this will be reflected in the Company's future financial results. Company assets have more than doubled since the beginning of the fiscal year, reflected by an increase in current assets, deferred tax asset, property and equipment.
AmeriGel's proprietary line of wound and skin care products is made with Oakin(TM), proven to enhance the natural healing of wounds, reduce inflammation and prevent infection. The AmeriGel professional line of products includes the flagship AmeriGel Hydrogel Wound Dressing, AmeriGel Saturated Gauze Pads, AmeriGel Post-OP Surgical Kits, AmeriGel Care Lotion, AmeriGel Barrier Lotion and AmeriGel Wound Wash.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: When used in this release, the words "may," "will," "expect," "anticipate," "continue," "estimate," "project," "intend," "believe," and similar expressions, variations or the negative of these words, and any statement regarding possible or assumed future results of operations of our business, the markets for our products, anticipated expenditures, regulatory developments or competition, or other statements regarding matters that are not historical facts, are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Such forward-looking statements are subject to various risks and uncertainties, including, but not limited to, the following: business conditions in the skin and wound care market and the general economy, competitive factors, changes in product mix, production delays, manufacturing capabilities, and other risks or uncertainties detailed in other of the Company's Securities and Exchange Commission filings. Additional information on these and other factors that could affect our financial results is included in our Form 10-KSB for the year ended June 30, 2006. There may be other factor not mentioned above, in the discussion below or included in our Securities and Exchange Commission filings that may cause actual results to differ materially from any forward-looking statements. The reader should not place undue reliance on any forward-looking statements. Neither the Company nor any of its corporate officers or key employees assumes any obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Contact:
Regina W. Anderson
rwa@procyondirect.com
727-447-2998
This is my little secret....
Now trading at a secret trailing PE of 5.4
a secret MKT cap of $2.4 mil
BTW.. solid history... growing little by little.....
News.... Procyon Reports Fifteenth Consecutive Profitable Quarter
CLEARWATER, FL -- (MARKET WIRE) -- February 23, 2007 -- Procyon Corporation (OTCBB: PCYN), a Florida-based company, whose subsidiaries include Amerx Health Care Corporation -- www.Amerigel.com -- and Sirius Medical Supply -- www.siriusmedical.com -- released its 10-QSB for Quarterly Period Ended December 31, 2006. The report reflects the 15th consecutive quarter that Procyon Corporation has posted a profit for its operations. Net sales for the first half of the fiscal year increased to approximately $1,152,859, an increase of approximately 7% over the same period one year ago. Sales increase was a result of expanding the Amerx distributor base and to increased volumes produced by existing distributors. Gross profit for the same six months was approximately $880,087, reflecting a 7% increase over the same period of the prior fiscal year. Gross profit was approximately 76% of net sales for this period. Full report can be found in the latest 10-QSB filing of 02/15/07.
Operating expenses increased as the company sought to expand its operations by purchasing the office building previously leased. The purchase increased the Company's asset base thus enabling Procyon to fund future growth needs. The Company also purchased and implemented a new accounting/inventory management software program that is expected to be more suitable for growth needs. Additional costs were incurred in this reporting period to launch a new product into the AmeriGel professional line of proprietary wound and skin care products. The initial response to the Post-Surgical Kit indicates that it is being well received by the health care industry and management anticipates this will be reflected in the Company's future financial statements.
AmeriGel proprietary line of wound and skin care products are made with Oakin™, proven to enhance the natural healing of wounds, reduce inflammation and prevent infection. The AmeriGel professional line of products includes the flagship AmeriGel Hydrogel Wound Dressing, AmeriGel Saturated Gauze Pads, AmeriGel Post-OP Surgical Kits, AmeriGel Care Lotion, AmeriGel Barrier Lotion and AmeriGel Wound Wash.
I can safely say I'm the only buyer of this stock in 2007!!!!
Never owned one like this... lol
Key to future may be in bold...
physician and government markets.
Future Developments
Amerx expects to further penetrate the podiatric market through its participation in industry trade shows, advertisements in trade journals, development of additional distributor relationships, opening new geographical territories (including foreign markets), and coordinating with physicians and educational institutions to provide training to the wound care and podiatric professional. Amerx management seeks to develop new products for the podiatric market as new needs become known through its association with health care professionals.
Amerx intends to pursue potential product developments in other medical disciplines including dermatology, veterinary care and other wound care applications. Preliminary investigations of these markets are ongoing.
Management anticipates further pursuing increased marketing efforts in its primary institutional wound care market as a result of the Amerigel Saturated Gauze Dressing being granted a Medicare HCPCS Reimbursement Code in 2004.
Sirius intends to aggressively attempt to add to its current customer base through the use of advertising, direct physician contact, referrals and possible acquisition of similar business entities. We believe that product lines will increase as customer needs dictate and economics allow.
Results of Operations
Comparison of Fiscal 2006 and 2005.
Net sales during fiscal 2006 were approximately $2,313,000 as compared to approximately $2,198,000 in fiscal 2005, an increase of approximately $115,000, or 5%. We believe that this increase is primarily attributable to our continuing marketing efforts and growth of our customer base. Sales growth in Sirius slowed to a 0.2% reduction in sales, while Amerx increased sales by 6%, respectively, over the previous year. Amerx is encouraged by the sales increase since its emphasis shifted to the physician market. Amerx hopes to capture more of the physician market in fiscal 2007, as well as penetrate new markets, such as government contracts and dermatology. Sirius's customer base is expanding with marketing efforts, and the Company continues such expansion with marketing efforts as well as product line expansion.
Will be watching for what you find out.
Marked the PCYN board and may join the ranks of investor soon.
it's on a short watch list of high potential medium-long term investments.
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
72
|
Created
|
11/04/06
|
Type
|
Free
|
Moderators |
Procyon Corporation (PCYN.OB), through its subsidiaries, engages in the development and marketing of medical products used in the treatment of pressure ulcers, dermatitis, inflammation, and other skin problems in the United States.
Subsidiaries
http://www.amerigel.com/
Share Structure
Common: 8,049,588
Preferred stock (Series A) (One = One Common) : 204,900 and receives Dividend of about $.026/share
Filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000812306
Yahoo: http://finance.yahoo.com/q?s=pcyn.ob
Recent News: http://search.marketwire.com/search/searchsimple.do?keywords=pcyn&newsearch=Y&sortby=date
World Diabetic research Foundation Directors: http://www.wdrf.org/directors.php
PROCYON CORPORATION & SUBSIDIARIES CONSOLIDATED BALANCE SHEETS | |||||||||
June 30, 2011 and 2010 | |||||||||
2011 | 2010 | ||||||||
ASSETS | |||||||||
CURRENT ASSETS | |||||||||
Cash | $ | 721,054 | $ | 827,512 | |||||
Certificate of Deposits, and accrued interest | 155,142 | 54,028 | |||||||
Accounts receivable, less allowance for doubtful | |||||||||
accounts of $1,000. | 311,493 | 184,130 | |||||||
Inventories | 204,733 | 188,287 | |||||||
Prepaid expenses | 147,449 | 116,815 | |||||||
Other Receivable | 8,762 | - | |||||||
Deferred tax asset | 140,577 | 121,391 | |||||||
TOTAL CURRENT ASSETS | 1,689,210 | 1,492,163 | |||||||
PROPERTY AND EQUIPMENT, NET | 535,040 | 513,925 | |||||||
OTHER ASSETS | |||||||||
Deposits | 792 | 1,854 | |||||||
Deferred tax asset | 724,681 | 861,945 | |||||||
725,473 | 863,799 | ||||||||
TOTAL ASSETS | $ | 2,949,723 | $ | 2,869,887 | |||||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||
CURRENT LIABILITIES | |||||||||
Accounts Payable | $ | 130,453 | $ | 184,942 | |||||
Accrued Expenses and Other | 146,753 | 128,006 | |||||||
Current Portion of Mortgage Payable | 32,211 | 26,335 | |||||||
TOTAL CURRENT LIABILITIES | 309,417 | 339,283 | |||||||
LONG-TERM LIABILITIES | |||||||||
Mortgage Payable | 314,173 | 397,367 | |||||||
TOTAL LONG TERM LIABILITIES | 314,173 | 397,367 | |||||||
STOCKHOLDERS' EQUITY | |||||||||
Preferred stock, 496,000,000 shares authorized, | |||||||||
none issued | - | - | |||||||
Series A Cumulative Convertible Preferred stock, | |||||||||
no par value; 4,000,000 shares authorized; 199,100 | |||||||||
shares issued and outstanding | 154,950 | 154,950 | |||||||
Common stock, no par value, 80,000,000 shares | |||||||||
authorized; 8,055,388 shares issued and outstanding | 4,416,676 | 4,416,676 | |||||||
Paid-in Capital | 6,000 | 6,000 | |||||||
Accumulated deficit | (2,251,493 | ) | (2,444,389 | ) | |||||
TOTAL STOCKHOLDERS' EQUITY | 2,326,133 | 2,133,237 | |||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 2,949,723 | $ | 2,869,887 | |||||
The accompanying notes are an integral part of these financial statements. | |||||||||
F - 2 |
PROCYON CORPORATION & SUBSIDIARIES | |||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||
Years Ended June 30, 2011 and 2010 | |||||||||
2011 | 2010 | ||||||||
NET SALES | $ | 2,701,996 | $ | 2,547,365 | |||||
COST OF SALES | 596,892 | 542,793 | |||||||
GROSS PROFIT | 2,105,104 | 2,004,572 | |||||||
OPERATING EXPENSES | |||||||||
Salaries and Benefits | 951,169 | 981,870 | |||||||
Selling, General and Administrative | 818,610 | 840,666 | |||||||
1,769,779 | 1,822,536 | ||||||||
INCOME FROM OPERATIONS | 335,325 | 182,036 | |||||||
OTHER INCOME (EXPENSE) | |||||||||
Interest Income | 2,726 | 6,664 | |||||||
Other Expense | (16 | ) | - | ||||||
Interest Expense | (27,633 | ) | (32,075 | ) | |||||
(24,923 | ) | (25,411 | ) | ||||||
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES | 310,402 | 156,625 | |||||||
INCOME TAX (EXPENSE) | (117,863 | ) | (58,787 | ) | |||||
NET INCOME FROM CONTINUING OPERATIONS | 192,539 | 97,838 | |||||||
DISCONTINUED OPERATIONS | |||||||||
Income from Operations of Discontinued Component | 573 | 39,979 | |||||||
Provision for Income Tax (Expense) | (216 | ) | (15,044 | ) | |||||
NET INCOME FROM DISCONTINUED OPERATIONS | 357 | 24,935 | |||||||
NET INCOME | 192,896 | 122,773 | |||||||
Dividend requirements on preferred stock | (19,910 | ) | (19,910 | ) | |||||
Basic net income available to common shares | $ | 172,986 | $ | 102,863 | |||||
Basic net income per common share | |||||||||
Continuing Operations | $ | 0.02 | $ | 0.01 | |||||
Discontinued Operations | $ | - | $ | - | |||||
Total Basic Net Income Per Share | $ | 0.02 | $ | 0.01 | |||||
Weighted average number of common shares outstanding | 8,055,388 | 8,055,388 | |||||||
Diluted net income per common share | |||||||||
Continuing Operations | $ | 0.02 | $ | 0.01 | |||||
Discontinued Operations | $ | - | $ | - | |||||
Total Diluted Net Income Per Share | $ | 0.02 | $ | 0.01 | |||||
Weighted average number of common shares | 8,254,488 | 8,254,488 | |||||||
outstanding, diluted | |||||||||
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |